A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Legend Biotech Corp stock. As of the latest transaction made, Bridgewater Associates, LP holds 165,459 shares of LEGN stock, worth $6.65 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
165,459
Previous 208,900 20.8%
Holding current value
$6.65 Million
Previous $11.7 Million 37.46%
% of portfolio
0.04%
Previous 0.06%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$39.5 - $57.22 $1.72 Million - $2.49 Million
-43,441 Reduced 20.8%
165,459 $7.33 Million
Q1 2024

May 14, 2024

SELL
$55.06 - $69.99 $6.67 Million - $8.48 Million
-121,191 Reduced 36.71%
208,900 $11.7 Million
Q4 2023

Feb 14, 2024

SELL
$57.25 - $69.74 $1.26 Million - $1.53 Million
-22,000 Reduced 6.25%
330,091 $19.9 Million
Q3 2023

Nov 13, 2023

BUY
$63.16 - $76.5 $922,514 - $1.12 Million
14,606 Added 4.33%
352,091 $23.6 Million
Q2 2023

Aug 11, 2023

BUY
$46.28 - $75.01 $2.71 Million - $4.39 Million
58,543 Added 20.99%
337,485 $23.3 Million
Q1 2023

May 12, 2023

SELL
$43.42 - $57.37 $7.58 Million - $10 Million
-174,681 Reduced 38.51%
278,942 $13.5 Million
Q4 2022

Feb 13, 2023

SELL
$38.8 - $55.46 $6.35 Million - $9.08 Million
-163,727 Reduced 26.52%
453,623 $22.6 Million
Q3 2022

Nov 10, 2022

BUY
$38.15 - $57.1 $1.75 Million - $2.61 Million
45,763 Added 8.01%
617,350 $25.2 Million
Q2 2022

Aug 11, 2022

BUY
$33.54 - $55.0 $951,898 - $1.56 Million
28,381 Added 5.22%
571,587 $31.4 Million
Q1 2022

May 13, 2022

BUY
$31.02 - $48.18 $13.2 Million - $20.6 Million
427,047 Added 367.64%
543,206 $19.7 Million
Q4 2021

Feb 14, 2022

BUY
$41.14 - $56.98 $4.78 Million - $6.62 Million
116,159 New
116,159 $5.41 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.73B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.